Characteristic | T group (n = 61) | TC group (n = 34) | P |
---|---|---|---|
Gender | 0.110 | ||
Male | 22(36.07) | 18(52.94) | |
Female | 39(63.93) | 16(47.06) | |
Age | 0.440 | ||
< 60 | 39 (63.93) | 19 (55.88) | |
≥ 60 | 22 (36.07) | 15 (44.12) | |
Smoking history | 0.949 | ||
No | 47 (77.05) | 26 (76.47) | |
Yes | 14 (22.95) | 8 (23.53) | |
ECOG PS | 0.646 | ||
0–1 | 58 (95.08) | 33 (97.06) | |
2 | 3 (4.92) | 1 (2.94) | |
Histology | 0.257 | ||
Adenocarcinoma | 60 (98.36) | 32 (94.12) | |
Non-adenocarcinoma | 1 (1.64) | 2 (5.88) | |
Clinical Stage | 0.719 | ||
IIIB/C | 9 (14.75) | 6 (17.65) | |
IV | 34 (55.74) | 16 (47.06) | |
IV with BM | 18 (29.51) | 12 (35.29) | |
Types of EGFR-TKIs | 0.557 | ||
Gefitinib | 41 (67.20) | 26 (76.47) | |
Icotinib | 13 (21.31) | 5 (14.71) | |
Erlotinib | 2 (3.29) | 2 (5.88) | |
Osimertinib | 5 (8.20) | 1 (2.94) | |
T790M status | 0.686 | ||
Negative | 17 (27.87) | 7 (20.59) | |
Positive | 28 (45.90) | 16 (47.06) | |
Unknow | 16 (26.23) | 11 (32.35) | |
EGFR mutation | 0.471 | ||
EGFR19 Del | 32(52.46) | 16(47.06) | |
EGFR21 L858R | 22(36.07) | 16(47.06) | |
Other mutations | 7(11.47) | 2(5.88) | |
TP53 mutation | 0.810 | ||
Exon4 | 6(9.83) | 1(2.94) | |
Exon5 | 17(27.87) | 11(32.35) | |
Exon6 | 4(6.57) | 2(5.88) | |
Exon7 | 14(22.95) | 10(29.41) | |
Exon8 | 12(19.67) | 5(14.71) | |
Other mutations | 8(13.11) | 5(14.71) |